Cannabis Policy Shift in US Doesn’t Move the Money

Cannabis Policy Shift in US Doesn’t Move the Money

Global Finance Magazine
Global Finance MagazineApr 30, 2026

Companies Mentioned

Why It Matters

Banking restrictions keep cannabis businesses dependent on cash, inflating security costs and deterring institutional investment, which hampers the sector’s scalability and financial stability.

Key Takeaways

  • Rescheduling to Schedule III leaves most cannabis firms cash‑only.
  • Large MSOs already have limited banking; small operators still excluded.
  • SAFER Banking Act remains stalled, blocking safe‑harbor for banks.
  • Visa, Mastercard unlikely to process cannabis payments after rescheduling.
  • Cash‑heavy operations raise compliance costs and security risks.

Pulse Analysis

The recent Schedule III reclassification marks a symbolic win for medical cannabis advocates, but its practical effect on financial services is minimal. By moving the plant from the most restrictive schedule, the federal government acknowledges therapeutic value and eases some tax burdens, yet it stops short of legalizing the substance. This nuanced shift does not alter the underlying federal illegality that forces banks to treat cannabis transactions as high‑risk, leaving payment processors like Visa and Mastercard unchanged in their refusal to support the industry.

For the sector’s smaller players, the banking bottleneck remains the most pressing obstacle. Without a federal safe‑harbor, banks risk penalties and asset forfeiture if they service state‑licensed growers, prompting many to stay out of the market entirely. The bipartisan SAFER Banking Act, introduced in 2023, would shield financial institutions from such repercussions, but it has stalled in Congress despite upcoming hearings. Until legislation passes, cannabis operators must rely on cash‑intensive models, incurring higher security expenses, cumbersome accounting, and limited access to credit lines that could fund expansion or technology upgrades.

The broader market implications are significant. Persistent cash reliance curtails the ability of cannabis firms to attract mainstream investors, hampers cross‑border financing, and limits the development of ancillary services such as fintech solutions. While the Schedule III move may spur research and modest tax relief, true financial integration hinges on legislative action. Stakeholders are watching the SAFER Act’s progress closely, recognizing that its enactment could unlock a wave of institutional capital, streamline compliance, and finally align the industry’s financial plumbing with its rapid revenue growth.

Cannabis Policy Shift in US Doesn’t Move the Money

Comments

Want to join the conversation?

Loading comments...